Trial Profile
A retrospective trial to assess potential biomarkers and treatment with lapatinib, in combination with capecitabine, in patients with HER2-positive advanced breast cancer who previously progressed on trastuzumab-based therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2015
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 07 Apr 2015 New trial record